DILIsym Services, Inc. was incorporated in 2014 and operates in Research Triangle Park, North Carolina. DILIsym Services, Inc. is committed to providing the pharmaceutical industry with the tools, resources and information to more efficiently develop safe and effective drug therapies that increase the availability of vital therapeutics for the patients who need them. DILIsym Services, Inc. has developed the DILIsym® modeling software and the NAFLDsym® modeling software to support these objectives. DILIsym Services, Inc. makes this software available to pharmaceutical companies in addition to performing services projects with the modeling software. In these projects, the DILIsym Services, Inc. expert scientific team engages clients from initial program design through data input and results interpretation.
Our mission is to help ensure the safety of drug therapies by leveraging our expertise in the areas of drug-induced liver injury, metabolic diseases, and modeling and simulation. We aim to make drug development more efficient for the pharmaceutical industry by informing key decisions, which will in turn lead to increased availability of vital medicines for the patients who need them.
DILIsym® Services may be utilized by companies involved in the research and development of drugs or chemicals, including services such as conducting simulations of drug-liver interactions, and designing computer software for companies to be used in modeling liver responses to a drug or chemical.
DILIsym Services, Inc. has the overarching goal of applying the DILIsym software to improve the safety profiles of therapeutics reaching the market. To achieve this goal, three significant objectives have been developed:
- Inform and impact the candidate selection process for therapeutic development teams in the preclinical development space as they prioritize the progression of compounds not yet taken into man;
- Provide information regarding the risk aspect of the risk versus benefit question often debated as large investments are considered to progress compounds from early stage clinical development to later stage, larger trials;
- Identify and/or substantiate precision medicine approaches from a safety perspective that may allow therapeutics to reach a majority of the target patient population without harming a few.
DILIsym Services also has the goal of aiding the successful development of medicines to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This goal is accomplished via the use of our newest product, NAFLDsym, to partner with pharmaceutical companies in this endeavor.
DSSI has multiple software platforms to support biotechnology and pharmaceutical companies in the development of safe and effective treatments. These software platforms support DILI-sim Initiative and DSSI goals of improving patient safety, reducing the need for animal testing, and reducing the costs and time necessary to develop new drugs. Click on the software titles on the right hand column to learn more.